{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".089","upperLimit":".287","value":".17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Very good partial response or better was defined per International Uniform Response criteria (Durie B, Harousseau JL, Miquel JS, et al Leukemia 2006). See CR requirements in primary outcome measure plus if serum and urine M protein were unmeasurable then immunoglobulin free light chain (FLC) must be in a normal ratio of 0.26-1.65 at two consecutive times. VGPR required the following: Serum and urine M-component detectable by immunofixation but not on electrophoresis; \\>=90% reduction in serum M-component plus urine M-component \\<100 mg per 24 hours (by SPEP and UPEP); if the serum and urine M protein were unmeasurable then a \\>90% decrease in the difference between involved and uninvolved FLC levels.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.","id":"OG000","title":"Bortezomib"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of eligible and treated participants.","reportingStatus":"POSTED","timeFrame":"Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).","title":"Very Good Partial Response (VGPR) Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}